M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images.
Shotaro Kanao,Shotaro Kanao,Masako Kataoka,Mami Iima,Debra M. Ikeda,Masakazu Toi,Kaori Togashi +6 more
TL;DR: For breast lesions with High T1 SI, segmenting the High T2 SI for ADC mapping distinguishes benign from malignant inflammatory conditions while using ADC mapping of the Low T2SI areas will not result in this distinction.
Journal ArticleDOI
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.
Masakazu Toi,M. Gion,Hisashi Saji,Asano Makoto,Ruggero Dittadi,S. Gilberti,N. Locopo,G. Gasparini +7 more
TL;DR: The balance between pro-angiogenic factors (TP and VEGF) and IL-12, as a detectable naturally occurring inhibitor of angiogenesis, is evaluated in the same series of node-negative and node-positive breast cancers.
Journal ArticleDOI
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy.
Monica S.M. Chan,Lin Wang,Lin Wang,Niramol Chanplakorn,Niramol Chanplakorn,Kentaro Tamaki,Takayuki Ueno,Masakazu Toi,Wings T.Y. Loo,Louis W.C. Chow,Takashi Suzuki,Hironobu Sasano +11 more
TL;DR: VPR could be a potential surrogate marker for predicting neoadjuvant endocrine therapy response, incorporating features of both carcinoma and stromal cells, in the early stage of neoadvuvantendocrine therapy before any discernible clinical and/or histopathological changes became apparent.
Journal ArticleDOI
Antitumor immunity and advances in cancer immunotherapy
Tomoharu Sugie,Masakazu Toi +1 more
TL;DR: Combination therapy using these methods involving neoantigens and checkpoint inhibitors may enable the achievement of an effective method to cure breast cancer in the near future.
Journal ArticleDOI
The Value of Lesion Size as an Adjunct to the BI-RADS-MRI 2013 Descriptors in the Diagnosis of Solitary Breast Masses.
Makiko Kawai,Masako Kataoka,Shotaro Kanao,Mami Iima,Natsuko Onishi,Akane Ohashi,Rena Sakaguchi,Masakazu Toi,Kaori Togashi +8 more
TL;DR: Lesion size is an independent contributor in diagnosing solitary breast masses and adding the information of lesion size to BI-RADS-MRI 2013 descriptors will allow more detailed categorizations.